Valion Bio, Inc. Common Stock (NASDAQ:VBIO) & KORU Medical Systems (NASDAQ:KRMD) Financial Survey

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and KORU Medical Systems (NASDAQ:KRMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Earnings and Valuation

This table compares Valion Bio, Inc. Common Stock and KORU Medical Systems”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780,000.00	3.50	-$8.88 million	($6.68)	-0.13
KORU Medical Systems	$41.13 million	4.58	-$2.64 million	($0.05)	-82.00

KORU Medical Systems has higher revenue and earnings than Valion Bio, Inc. Common Stock. KORU Medical Systems is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are owned by institutional investors. 14.5% of Valion Bio, Inc. Common Stock shares are owned by insiders. Comparatively, 18.5% of KORU Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Valion Bio, Inc. Common Stock and KORU Medical Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%
KORU Medical Systems	-5.27%	-13.61%	-8.33%

Volatility and Risk

Valion Bio, Inc. Common Stock has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500. Comparatively, KORU Medical Systems has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Valion Bio, Inc. Common Stock and KORU Medical Systems, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1	0	0	0	1.00
KORU Medical Systems	1	0	4	0	2.60

KORU Medical Systems has a consensus target price of $7.25, suggesting a potential upside of 76.83%. Given KORU Medical Systems’ stronger consensus rating and higher probable upside, analysts clearly believe KORU Medical Systems is more favorable than Valion Bio, Inc. Common Stock.

Summary

KORU Medical Systems beats Valion Bio, Inc. Common Stock on 11 of the 14 factors compared between the two stocks.

About Valion Bio, Inc. Common Stock

Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

About KORU Medical Systems

KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.